Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.
Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.
advertisement
With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
